NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$7.33
-0.08 (-1.08%)
Close of Nov 06, 2026 · end-of-day data
AHCO 8-K filings in 2025
Every material Form 8-K AdaptHealth filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AdaptHealth reported third-quarter 2025 results for the period ended September 30, 2025, with net revenue of $820.3 million, up 1.8% from $805.9 million a year earlier, and adjusted EBITDA of $170.1 million, up 3.5%. The company kept its fiscal 2025 guidance unchanged, including net revenue of $3.18 billion to $3.26 billion and adjusted EBITDA of $642 million to $682 million, and reported that net leverage was 2.68x against a 2.50x target.
Q3 net income attributable to AdaptHealth was $24.5 million, compared with $22.9 million a year earlier.
Q3 organic revenue growth was 5.1%, the highest since the first quarter of 2024, per the company.
Fiscal 2025 guidance maintained: net revenue $3.18 billion to $3.26 billion; free cash flow $170 million to $190 million.
Nine-month net income attributable to AdaptHealth was $32.0 million, down from $40.2 million, and nine-month free cash flow was $140.1 million, down from $162.7 million.
AdaptHealth reported second quarter 2025 net revenue of $800.4 million, down 0.7% from $806.0 million, and net income attributable to the company of $14.7 million, down from $19.4 million. The company lowered its full-year 2025 Adjusted EBITDA guidance to $642 million to $682 million from $662 million to $702 million, which matters to shareholders because both headline profit and the outlook weakened.
Net revenue was $800.4 million versus $806.0 million a year earlier, a decrease of 0.7%.
Adjusted EBITDA was $155.5 million versus $165.3 million, a decrease of 5.9%.
Full-year 2025 Adjusted EBITDA guidance was lowered to $642 million to $682 million from $662 million to $702 million.
Full-year 2025 net revenue guidance was narrowed to $3.18 billion to $3.26 billion from $3.15 billion to $3.29 billion; free cash flow guidance of $170 million to $190 million was unchanged.
AdaptHealth reported first-quarter 2025 net revenue of $777.9 million, down 1.8% from a year earlier, and a net loss attributable to the company of $7.2 million, compared with a $2.1 million loss in the prior-year quarter. Adjusted EBITDA fell 19.3% to $127.9 million. The company also lowered its fiscal 2025 net revenue and adjusted EBITDA guidance to account for the disposition of certain incontinence assets, reducing its outlook for shareholders.
Net revenue was $777.9 million, down from $792.5 million in the first quarter of 2024, a decrease of 1.8%.
Net loss attributable to AdaptHealth Corp. was $7.2 million, compared with a net loss of $2.1 million a year earlier.
Fiscal 2025 net revenue guidance was lowered to $3.18 billion to $3.32 billion from $3.22 billion to $3.36 billion; adjusted EBITDA guidance was lowered to $665 million to $705 million from $670 million to $710 million.
Free cash flow guidance of $180 million to $220 million was unchanged; first-quarter cash flow from operations was $95.5 million.
AdaptHealth reported fourth-quarter and full-year 2024 results on February 25, 2025, and gave 2025 guidance. Fourth-quarter net revenue and adjusted EBITDA each fell slightly from the prior-year quarter, while full-year net revenue and adjusted EBITDA rose, and net income swung to a profit of $90.4 million from a loss of $678.9 million. The company's 2025 guidance calls for net revenue of $3.22 billion to $3.36 billion and adjusted EBITDA of $670 million to $710 million.
Q4 2024 net revenue was $856.6 million, down 0.2% from $858.2 million; Q4 adjusted EBITDA was $200.6 million, down 2.0%.
Full-year 2024 net revenue was $3.26 billion, up 1.9%, and adjusted EBITDA was $688.7 million, up 2.7%.
Full-year 2024 net income attributable to AdaptHealth was $90.4 million, compared with a loss of $678.9 million in 2023, which included an $830.8 million goodwill impairment.
2025 guidance: net revenue of $3.22 billion to $3.36 billion, adjusted EBITDA of $670 million to $710 million, and free cash flow of $180 million to $220 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AdaptHealth filing is on SEC EDGAR ↗. 8-K briefs of other companies →